{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:00Z","timestamp":1789635720161,"version":"4.0.0"},"reference-count":58,"publisher":"Portland Press Ltd.","issue":"10","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/n\/a","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3400700"],"award-info":[{"award-number":["2022YFC3400700"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"National Nature Science foundation of China","doi-asserted-by":"publisher","award":["82370397"],"award-info":[{"award-number":["82370397"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"National Nature Science foundation of China","doi-asserted-by":"publisher","award":["82100402"],"award-info":[{"award-number":["82100402"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"National Nature Science foundation of China","doi-asserted-by":"publisher","award":["U22A20266"],"award-info":[{"award-number":["U22A20266"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/n\/a","name":"Hubei provincial Nature Science Foundation","doi-asserted-by":"publisher","award":["2025CSA042"],"award-info":[{"award-number":["2025CSA042"]}],"id":[{"id":"10.13039\/n\/a","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium\u2013glucose transport protein 2 inhibitors (SGLT2i), initially developed as antidiabetic agents and now established as foundational therapies for heart failure, have also shown antihypertensive effects in clinical trials involving patients with diabetes and heart failure. However, the underlying mechanisms remain incompletely understood. Given the diverse roles of arachidonic acid (AA) and its metabolites in blood pressure regulation, we investigated the antihypertensive effects of SGLT2i in hypertensive patients and an animal model and explored whether modulation of AA metabolism contributes to these effects. We first confirmed the antihypertensive effects of SGLT2i in a retrospective cohort study and spontaneously hypertensive rats (SHRs). Targeted metabolomic analysis of plasma and tissues from SHRs identified 20-hydroxyeicosatetraenoic acid (20-HETE) originating from the renal cortex as a key metabolite modulated by SGLT2i. Among the enzymes responsible for 20-HETE production, CYP4A but not CYP4F was found to be down-regulated by dapagliflozin at both mRNA and protein levels. Immunofluorescence colocalization further localized this effect to proximal tubular epithelial cells, where SGLT2i reduced CYP4A expression and subsequent 20-HETE production, leading to attenuated renal inflammation, fibrosis, and blood pressure elevation. Together, these findings not only confirm the antihypertensive effects of SGLT2i but also delineate a novel antihypertensive mechanism by which lower blood pressure, demonstrating that modulation of AA metabolism contributes partially to their blood pressure-lowering effects.<\/jats:p>","DOI":"10.1042\/bsr20260150","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:10:00Z","timestamp":1788516600000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitor ameliorates hypertension by regulating the CYP4A\/20-HETE pathway in the kidney"],"prefix":"10.1042","volume":"46","author":[{"given":"Zhitong","family":"Zhou","sequence":"first","affiliation":[{"name":"1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Hang","sequence":"additional","affiliation":[{"name":"1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-0414","authenticated-orcid":false,"given":"Junfang","family":"Wu","sequence":"additional","affiliation":[{"name":"1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9774-3980","authenticated-orcid":false,"given":"Dao\u00a0Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026091704065570500_B1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","article-title":"Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension","volume":"18","author":"Zhou","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"2026091704065570500_B2","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","article-title":"A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension","volume":"388","author":"Olsen","year":"2016","journal-title":"Lancet"},{"key":"2026091704065570500_B3","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Collaborators G.B.D.R.F.","year":"2018","journal-title":"Lancet"},{"key":"2026091704065570500_B4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Collaboration N.C.D.R.F.","year":"2021","journal-title":"Lancet"},{"key":"2026091704065570500_B5","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"2026091704065570500_B6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B12","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"2026091704065570500_B13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure","volume":"28","author":"Writing Committee","year":"2022","journal-title":"J. Card. Fail."},{"key":"2026091704065570500_B14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"2026091704065570500_B16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2026091704065570500_B17","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.3390\/ijms20153683","article-title":"Arachidonic acid metabolism and kidney inflammation","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2026091704065570500_B18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"2026091704065570500_B19","doi-asserted-by":"publisher","first-page":"12029","DOI":"10.3390\/ijms222112029","article-title":"Effects of arachidonic acid metabolites on cardiovascular health and disease","volume":"22","author":"Zhou","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026091704065570500_B20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.33549\/physiolres.934291","article-title":"Epoxyeicosanoids in hypertension","volume":"68","author":"Imig","year":"2019","journal-title":"Physiol. Res."},{"key":"2026091704065570500_B21","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/CIRCRESAHA.116.310525","article-title":"20-HETE signals through G-protein-coupled receptor GPR75 (G(q)) to affect vascular function and trigger hypertension","volume":"120","author":"Garcia","year":"2017","journal-title":"Circ. Res."},{"key":"2026091704065570500_B22","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/HYPERTENSIONAHA.124.21718","article-title":"20-HETE and hypertension","volume":"81","author":"Roman","year":"2024","journal-title":"Hypertension"},{"key":"2026091704065570500_B23","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2026091704065570500_B24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"2026091704065570500_B25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12890-022-01939-7","article-title":"Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension","volume":"22","author":"Tang","year":"2022","journal-title":"BMC Pulm. Med."},{"key":"2026091704065570500_B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ptr.4966","article-title":"Animal studies on medicinal herbs: predictability, dose conversion and potential value","volume":"28","author":"Wojcikowski","year":"2014","journal-title":"Phytother. Res."},{"key":"2026091704065570500_B27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1021\/pr501200u","article-title":"Systematic metabolomic analysis of eicosanoids after omega-3 polyunsaturated fatty acid supplementation by a highly specific liquid chromatography-tandem mass spectrometry-based method","volume":"14","author":"Zhang","year":"2015","journal-title":"J. Proteome Res."},{"key":"2026091704065570500_B28","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1159\/000189154","article-title":"Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat","volume":"73","author":"Schwartzman","year":"1996","journal-title":"Nephron"},{"key":"2026091704065570500_B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev.pharmtox.45.120403.100045","article-title":"Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation","volume":"45","author":"Kroetz","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2026091704065570500_B30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pharmthera.2018.07.004","article-title":"20-HETE in the regulation of vascular and cardiac function","volume":"192","author":"Rocic","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"2026091704065570500_B31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"2026091704065570500_B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"2026091704065570500_B33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"2026091704065570500_B34","doi-asserted-by":"publisher","first-page":"e025328","DOI":"10.1161\/JAHA.121.025328","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin antagonizes salt-sensitive hypertension through modifying transient receptor potential channels 3 mediated vascular calcium handling","volume":"11","author":"Zhao","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"2026091704065570500_B35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet. Med."},{"key":"2026091704065570500_B36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes. Meta."},{"key":"2026091704065570500_B37","doi-asserted-by":"publisher","first-page":"999254","DOI":"10.3389\/fcvm.2022.999254","article-title":"Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy","volume":"9","author":"Xi","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"2026091704065570500_B38","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.2147\/DMSO.S422327","article-title":"Metabolic and hepatic effects of empagliflozin on nonalcoholic fatty liver Mice","volume":"16","author":"Niu","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"2026091704065570500_B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apha.2022.02.003","article-title":"The CYP\/20-HETE\/GPR75 axis in hypertension","volume":"94","author":"Froogh","year":"2022","journal-title":"Adv. Pharmacol."},{"key":"2026091704065570500_B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ki.2010.377","article-title":"Inhibition of 20-HETE synthesis and action protects the kidney from ischemia\/reperfusion injury","volume":"79","author":"Hoff","year":"2011","journal-title":"Kidney Int."},{"key":"2026091704065570500_B41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejphar.2018.06.010","article-title":"Conflicting roles of 20-HETE in hypertension and renal end organ damage","volume":"833","author":"Zhang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"2026091704065570500_B42","doi-asserted-by":"publisher","first-page":"2611130","DOI":"10.1080\/10641963.2025.2611130","article-title":"Arachidonic acid intake promotes hypertension and target-organ fibrosis through CYP4A-mediated 20-HETE overproduction: integrated evidence from human and animal studies","volume":"48","author":"Zhou","year":"2026","journal-title":"Clin. Exp. Hypertens."},{"key":"2026091704065570500_B43","doi-asserted-by":"publisher","first-page":"bqab079","DOI":"10.1210\/endocr\/bqab079","article-title":"SGLT2 inhibitors as calorie restriction mimetics: insights on longevity pathways and age-related diseases","volume":"162","author":"Hoong","year":"2021","journal-title":"Endocrinology"},{"key":"2026091704065570500_B44","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors\u2014perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"eBioMedicine"},{"key":"2026091704065570500_B45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13098-026-02193-1","article-title":"Advances in targeted treatment of ferroptosis in diabetic kidney disease with SGLT2 inhibitors","volume":"18","author":"Chen","year":"2026","journal-title":"Diabetol. Metab. Syndr."},{"key":"2026091704065570500_B46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","article-title":"Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway","volume":"195","author":"Lu","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"2026091704065570500_B47","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026091704065570500_B48","doi-asserted-by":"publisher","first-page":"2546624","DOI":"10.1080\/0886022X.2025.2546624","article-title":"Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6\/HIF-1\u03b1 signaling","volume":"47","author":"Wang","year":"2025","journal-title":"Ren. Fail."},{"key":"2026091704065570500_B49","doi-asserted-by":"publisher","first-page":"R934","DOI":"10.1152\/ajpregu.00125.2018","article-title":"High-fat diet-induced obesity and insulin resistance in CYP4a14(-\/-) mice is mediated by 20-HETE","volume":"315","author":"Gilani","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2026091704065570500_B50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1748-1716.1984.tb00133.x","article-title":"Renal sympathetic activity in spontaneously hypertensive rats and normotensive controls, as studied by three different methods","volume":"120","author":"Lundin","year":"1984","journal-title":"Acta Physiol. Scand."},{"key":"2026091704065570500_B51","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1113\/jphysiol.2008.165902","article-title":"Amplified respiratory-sympathetic coupling in the spontaneously hypertensive rat: does it contribute to hypertension?","volume":"587","author":"Simms","year":"2009","journal-title":"J. Physiol."},{"key":"2026091704065570500_B52","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1097\/00004872-199816121-00019","article-title":"Role of the sympathetic nervous system in human hypertension","volume":"16","author":"Grassi","year":"1998","journal-title":"J. Hypertens."},{"key":"2026091704065570500_B53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J. Cardiol."},{"key":"2026091704065570500_B54","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/s41440-025-02216-w","article-title":"Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states","volume":"48","author":"Katsurada","year":"2025","journal-title":"Hypertens Res."},{"key":"2026091704065570500_B55","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1161\/HYPERTENSIONAHA.122.19177","article-title":"Dapagliflozin attenuates sympathetic and pressor responses to stress in young prehypertensive spontaneously hypertensive rats","volume":"79","author":"Kim","year":"2022","journal-title":"Hypertension"},{"key":"2026091704065570500_B56","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J. Am. Soc. Hypertension"},{"key":"2026091704065570500_B57","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1161\/HYP.0000000000000090","article-title":"Animal models of hypertension: a scientific statement from the American Heart Association","volume":"73","author":"Lerman","year":"2019","journal-title":"Hypertension"},{"key":"2026091704065570500_B58","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J. Mol. Cell Cardiol."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20260150\/991875\/bsr-2026-0150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20260150\/991875\/bsr-2026-0150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:07:05Z","timestamp":1789632425000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/46\/10\/BSR20260150\/238036\/SGLT2-inhibitor-ameliorates-hypertension-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20260150","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,17]]},"article-number":"BSR20260150"}}